





























77. Viswanathan V, Singh K P (2019) Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT). *Diabetes Technology & Therapeutics* 21: 415-422.
78. Jhund P, Solomon S, Docherty K, Heerspink H, Anand I, et al. (2020) Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection. *Fraction Circulation* 143: 298-309.
79. AstraZeneca's Dapagliflozin receives Marketing Authorisation for Chronic Kidney Disease in India (2021). Available online at <https://www.astrazeneca.in/media/press-releases/2020/astrazenecas-dapagliflozin-receives-marketing-authorisation-for-chronic-kidney-disease-in-india>
80. AstraZeneca's Dapagliflozin (Forxiga) approved in India for treatment of patients with Heart Failure with reduced ejection fraction (2020). Available online at <https://www.astrazeneca.in/content/az-in/media/press-releases/2020/astrazenecas-dapagliflozin-forxiga-approved-in-india-for-treatment-of-patients-with-heart-failure-with-reduced-ejection-fraction.html>.
81. Fernandez-Fernandez B, Sarafidis P, Kanbay M, Navarro-Gonzalez JF, Soler MJ, et al. (2020) SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. *Clin Kidney J* 13: 728-733.
82. Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, et al. (2020) DIAMOND investigators. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): A randomised double-blind crossover trial. *Lancet Diabetes Endocrinol* 8: 582-593.
83. Melillo G (2020) Panelists Argue for SGLT2 Inhibitors Uptake Among Nephrologists. *AJMC* Available online at <https://www.ajmc.com/view/panelists-argue-for-sgl-2-inhibitors-uptake-among-nephrologists>.
84. Norhammar A, Bodegard J, Nyström T, Thuresson M, Rikner K, et al. (2019) Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: a nationwide observational study. *Diabetes Obes Metab* 21: 2651-2659.
85. Williams DM, Evans M (2020) Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver. *Diabetes Ther* 11: 2207-2219.